Navigation Links
Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients

off" time (i.e., time when normal Parkinson's medication was ineffective and symptoms were troubling to the patient) and a doubling of good quality "on" time without dyskinesias (i.e., time when a patient is functioning well) according to self-reported diaries.

This Phase 1 clinical trial was partially supported by a grant from The Michael J. Fox Foundation for Parkinson's Research. Based on the results of the Phase 1 study, the Foundation has provided a $1.9 million grant, which will provide partial funding for Ceregene's ongoing Phase 2 trial.

"We are pleased with the results of this early study which suggests that the majority of patients treated with CERE-120 may have exhibited significant and stable improvement for a full year after receiving a single administration of CERE-120," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "Each of our products, much like CERE-120, is aimed at unmet neurodegenerative diseases including Parkinson's disease, Alzheimer's disease and Amyotrophic Lateral Sclerosis (AML or Lou Gehrig's disease) with the goal of not only improving the symptoms but also preventing progression of the disease."

"Through stereotactic surgery, we are able to administer CERE-120 in a highly targeted fashion to one area of the brain that Parkinson's disease affects, and we were able to do this safely," stated Dr. Starr.

"Given the encouraging data from the Phase 1 trial of CERE-120 in Parkinson's disease, we are conducting a follow-on Phase 2 clinical trial that is currently enrolling patients at nine clinical trial sites in the United States," said Raymond T. Bartus, Ph.D., Ceregene's senior vice president of clinical and preclinical R&D and chief operating officer. "The data from the Phase 1 trial are reflective of the impressive results we gathered from preclinical studies, which demonstrated the ability of CERE-120 to stimulate the survival and improve the function of key neuronal c
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:11/28/2008)...28 German biotech company,Partec ...HIV monitoring and,AIDS patient follow-up diagnos...e year 2008, 2.5 million patient tests have been p...ordable "CyFlow" system, supporting already,more ... introduction of the,Partec innovation, the avera...
(Date:11/26/2008)...utomation and intelligent clinical applications ta... level , , CHICAGO, Ill., Nov. 26 /PRNewswi...ens.com/healthcare ) highlights the ACUSON S2000(...e world,s first multi-use, automated volume breast...y and Annual Meeting of the Radiological Society o...
(Date:11/25/2008)...against expanding statin use broadly in wake of AH...ov. 25 JUPITER, a clinical trial s...r risk of healthy patients with elevated CRP, shou..., according to a national poll directed at health ...n the online poll conducted by medical news site M...
(Date:11/25/2008)...l Trial to Assess Survival of Patients Receiving L...able Hepatocellular Carcinoma , , BELLEVUE,...ology, Inc. (LSO) today announced the completion o... Light Infusion Therapy(TM) (Litx(TM)) as a treatm...), also known as hepatoma or primary liver cancer....
Breaking Medicine Technology:German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Veterans for Americas 28VFA 29 Wounded Warrior Outreach Program Responds to Fort Drum in Aftermath of Report 12408 1Veterans for Americas 28VFA 29 Wounded Warrior Outreach Program Responds to Fort Drum in Aftermath of Report 12408 2New York Strengthens Emergency Preparedness with Cardinal Health Ventilators 3443 1New York Strengthens Emergency Preparedness with Cardinal Health Ventilators 3443 2Accumetrics Announces 2428 8 Million Financing and Initiation of Pivotal Clinical Trial 1406 1Accumetrics Announces 2428 8 Million Financing and Initiation of Pivotal Clinical Trial 1406 2Major scientific push to tackle agricultural productivity and food security in developing world 2285 1Major scientific push to tackle agricultural productivity and food security in developing world 2285 2Major scientific push to tackle agricultural productivity and food security in developing world 2285 3
(Date:12/2/2008)...NDO, Fla., Dec. 2 MEDai, Inc., hea...olutions provider, has added a new module,to its ...The new stand-alone,module monitors a population,...s and alerts stakeholders when there has been a de... Navigator Guidelines(TM) provides,real-time deci...
(Date:12/2/2008)...inal Special Features MLS Stars and Promotes Healt.../ -- Juniper Content Corporation,s (OTC Bulletin ...astest-growing Spanish-language children,s network... special Juega Como un MLS Pro , the climax of th...ue Soccer, on Sunday, December 7th at 7 PM EST. ,...
(Date:12/2/2008)...cts to File NDA with FDA in Early to Mid-2009 , ... Rx, the developers of PharmFilm(R) technology and...g thin film pharmaceutical products, and Strativa ... of Par Pharmaceutical Companies, Inc. (NYSE: PR...all pivotal bioequivalence studies for a thin film...
(Date:12/2/2008)...IN, China, Dec. 2 /PRNewswire-Asia-FirstCall/ -- C...l" or "the Company") (Nasdaq: CSKI ), a leading,... over-the-counter drugs in,the People,s Republic ...(Stanley) Hao was appointed Chief Financial Office...y,s Board of Directors. He replaces Yu-kun Zhang,...
Breaking Medicine News(10 mins):Health News:MEDai Evidence-Based Guideline Reporting Provides Decision Support at Point of Care 2Health News:Sorpresa! Premieres Juega Como un MLS Pro 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 3
...or most teenagers a run up the stairs is simply th...or others the resulting breathlessness// and pound...icting a future vulnerability to panic symptoms. ...f Arkansas psychologist, has found that adolescent...
... certain gonorrhea strain has titillated the curio...enzyme, called prolyliminopeptidase//, which helps...s strain of gonorrhea. The existing diagnostic eva...w strain, making detection of gonorrhea extremely ...
... new research shows that nonsurgical embolization ...ecurrence rate and much quicker recovery than surg...eins in the testicle and scrotum). This condition ...ility problems—and can greatly impact quality of l...
...ew Delhi: India witnesses nearly 1.8 million tuber...menace the government// has cleared Rs. 11.56 bill...(RNTCP)-Phase II. As per government estimates, n...infected with TB bacillus but only 10 percent brea...
Other Medicine News:Health News:Panic may Lead to Serious Mental Health Problems in Adolescents 2Health News:Nonsurgical Therapy Highly Effective for Pain and Infertility in Men 2Health News:Government Allot More Funds for Revised TB Program 2
Standard reading test. "Clearing weather..."
Directional `E' and `C' test.
...These Low Contrast Flip charts contain 5 pages of ...ach page. Optotype size is 9.5M. Contrast levels a... can be used at several different distances. These...a different set of symbols to guard against memor...
...The PowerLab/4SP is a high-performance data acquis... applications including human and animal physiolog..., biochemistry, and biomedical engineering. The un...fast speeds (up to 200 000 samples per second cont...
Medicine Products: